Oxidative Stress News and Research

RSS

Oxidative Stress is a condition in which antioxidant levels are lower than normal. Antioxidant levels are usually measured in blood plasma.

Supplemental oxygen during stroke is effective to combat brain tissue damage

Scientists have countered findings of previous clinical trials by showing that giving supplemental oxygen to animals during a stroke can reduce damage to brain tissue surrounding the clot.

26 Oct 2009

AEOL 10150 increases regeneration of GI stem cells: NIAID study results

Aeolus Pharmaceuticals, Inc. announced today that recent experiments in preclinical models conducted by the National Institutes of Health’s (NIH), National Institute of Allergy and Infectious Diseases (NIAID) Radiation/Nuclear Medical Countermeasure Development program have shown that AEOL 10150 can effectively increase regeneration of gastro-intestinal (GI) stem cells, reduce the severity and duration of diarrhea and improve survival when administered at 24 hours after doses of total-body irradiation that produce the lethal GI syndrome.

23 Oct 2009

Plant-based foods could help fight obesity and heart disease

The cheeseburger and French fries might look tempting, but eating a serving of broccoli or leafy greens first could help people battle metabolic processes that lead to obesity and heart disease, a new University of Florida study shows.

22 Oct 2009

OXIS International retains Quinn Emanuel Urquhart Oliver & Hedges to enforce all patents related to L-Ergothioneine

OXIS INTERNATIONAL, INC. announced today that the Company has retained Quinn Emanuel Urquhart Oliver & Hedges (“Quinn Emanuel”) to enforce all patents related to the unique benefits of its potent antioxidant compound L-Ergothioneine (“ERGO”).

21 Oct 2009

APP balance critical for normal neuronal development

New data about amyloid precursor protein, or APP, a protein implicated in development of Alzheimer's disease, suggests it also may have a positive role -- directly affecting learning and memory during brain development. So is APP good or bad? Researchers at Georgetown University Medical Center say both, and that a balance of APP is critical.

19 Oct 2009

Current safety equipment may not be adequate for nanoprotection

Writing in a forthcoming issue of the International Journal of Nanotechnology, Canadian engineers suggest that research is needed into the risks associated with the growing field of nanotechnology manufacture so that appropriate protective equipment can be developed urgently.

14 Oct 2009

OXIS International to raise $2.0 million from sale of Convertible Debentures and Warrants

OXIS INTERNATIONAL, INC. announced today that the Company has entered into and closed agreements with several accredited investors to purchase Convertible Debentures and Warrants representing $2.0 million in gross proceeds.

12 Oct 2009

Synta Pharmaceuticals updates its Phase 3 SYMMETRY trial results at the Melanoma XIII Conference

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that additional results from its Phase 3 trial (SYMMETRYSM) of elesclomol in combination with paclitaxel in metastatic melanoma was presented at the Perspectives in Melanoma XIII Conference by Steven O’Day, M.D., principal investigator and Chief of Research and Director of the Melanoma Program at the Angeles Clinic in Santa Monica, California.

12 Oct 2009

Valensa initiates licensing patent for the use of the astaxanthin as a dietary supplement

Valensa International (Orlando, FL USA) announced today that it has initiated a broad out licensing effort for University of Illinois patent (US 5,527,533 and its foreign equivalents) for the use of the astaxanthin in eye healthcare dietary supplement applications.

8 Oct 2009

LifeVantage reduces operating costs and continues to expand network marketing business

LifeVantage Corporation (OTC Bulletin Board: LFVN), the maker of Protandim® and TrueScience(TM) Anti-Aging Cream, science-based solutions for oxidative stress, announced today that it has implemented reductions in operating costs while continuing to concentrate on the science behind its products and supporting the Company's ongoing expansion in the network marketing distribution channel.

8 Oct 2009

Aeolus Pharmaceuticals raises $1.65 million from existing institutional shareholders

Aeolus Pharmaceuticals, Inc. announced today that it has completed a $1.65 million financing with several existing institutional shareholders, all of which are affiliates of Xmark Opportunity Partners, LLC. Under the terms of the financing, Aeolus received $1.65 million in gross proceeds in exchange for 5,892,857 Units (the “Units”), with each Unit comprised of one share of Aeolus Pharmaceuticals common stock, and a seven year warrant to purchase up to two additional shares of Aeolus Pharmaceuticals common stock at an initial exercise price of $0.28 per share, for a per Unit purchase price of $0.28.

7 Oct 2009

UCF research team develops miniature diagnostic tool kit for dementia

With the risk of developing dementia growing at an alarming pace, a University of Central Florida research team is working with the Boston University School of Medicine to develop a miniature diagnostic toolkit in the hopes of stimulating earlier detection and treatment.

1 Oct 2009

Moderately elevated levels of ROS positive in fruit flies

It has been known for decades that reactive oxygen species (ROS) - ions or very small molecules that include free radicals - damage cells. But much to their surprise, Jonsson Cancer Center researchers found that in Drosophila, the common fruit fly, moderately elevated levels of ROS are a good thing.

25 Sep 2009

NIH awards $2.5 million grant to University of Utah cardiologist

A pioneering model that a University of Utah cardiologist proposes as a cause of heart disease is the kind of creative thinking the National Institutes of Health (NIH) likes to see-and reward with one of its most prestigious honors, a $2.5 million 2009 Pioneer Award.

24 Sep 2009

Alimera Sciences starts pilot study of Iluvien intravitreal insert

Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported that enrollment has begun for a pilot study to assess the safety and efficacy of Iluvien(R) in patients with macular edema secondary to retinal vein occlusion.

23 Sep 2009

Anavex completes manufacturing of Alzheimer's disease drug ANAVEX 2-73 for its clinical trials

Anavex Life Sciences Corp., ("ANAVEX") (OTCBB: AVXL) today announced the completion of scale-up manufacturing of ANAVEX 2-73, its lead compound for the treatment of Alzheimer's disease.

21 Sep 2009

Study compares annual healthcare costs of diabetic and non-diabetic individuals

Risk factors for metabolic syndrome, such as obesity, high blood pressure, and elevated blood lipid levels, can increase a person's healthcare costs nearly 1.6-fold, or about $2,000 per year. For each additional risk factor those costs rise an average of 24%, according to an illuminating article in a recent issue of Metabolic Syndrome and Related Disorders, a peer-reviewed journal published by Mary Ann Liebert, Inc.

18 Sep 2009

Dietary ingredient derived from melon relieves stress

A dietary ingredient derived from a melon rich in antioxidant superoxide dismutase enzymes has been shown to relieve stress. In a double-blind, randomised, placebo-controlled trial, published in BioMed Central's open access Nutrition Journal, researchers found that the supplement decreased the signs and symptoms of perceived stress and fatigue in healthy volunteers.

15 Sep 2009

Vivakor completes third-party validation testing of its VivaBlend nutraceutical product

Vivakor™, Inc. (OTCBB: VIVK) today announced the results of independent, third-party validation testing of its VivaBlend™ nutraceutical product. VivaBlend is a powerful extract developed by the scientists at Vivakor and is derived from over 18 highly bioactive fruits, vegetables and legumes. Through a proprietary formulation and extraction process, Vivakor scientists have maximized the health benefits of VivaBlend by creating an optimum blend of super-antioxidants and powerful plant phenolics and flavonoids.

14 Sep 2009

Aeolus commences second study of AEOL 10150 against Acute Radiation Syndrome

Aeolus Pharmaceuticals, Inc. (OTC Bulletin Board: AOLS) announced today the initiation of a second study, in mice, to determine the optimal length of treatment with AEOL 10150 when used as a countermeasure to Acute Radiation Syndrome (ARS) in the lungs. This study, led by Zeljko Vujaskovic, M.D. Ph.D. of Duke University, is designed to build on the recently completed study that demonstrated the efficacy of AEOL 10150 as a treatment for damage to the lungs due to exposure to radiation, and determine the most effective duration of delivery for treatment after exposure.